The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in patients with advanced malignancies.
SparkCures ID | 851 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 195 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers